Interestingly, EGFR signaling not only induces de novo expression of PD-L1 as shown in lung and head and neck cancer but also promotes stabilization of PD-L1 surface expression through glycosylation of its extracellular domain mediated by glycogen synthase kinase 3β (GSK3β) activation (Li et al., 2016). The gene discussed is CD274; the disease is head and neck cancer.